Leukoreduction Filters in Transfusion Medicine: 4 Factors That Matter Most
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, has shared a post on LinkedIn:
”Do all leukoreduction filters perform the same? Not really…
In transfusion medicine, not all filters are equal. Behind what looks like a simple device lie technical choices that directly impact patient safety and blood product quality. So… how do you know which one is the right filter?
Here are the 4 key criteria:
Leukoreduction performance
• European standard: ≤ 1 million residual white blood cells
• AABB standard: ≤ 5 million
In practice, users often expect a filter to perform 5 to 10 times better than these limits, to ensure stability and safety.
Residual losses
An efficient filter retains leukocytes… but it may also trap red blood cells. Too much loss = a direct impact on hemoglobin levels, or on the required minimum recovery (≥ 85% according to AABB). The challenge is to find the right balance.
Filtration speed
Some centers want ultra-fast processing. Others prefer quality over speed. It all depends on the number of units to process daily and the available “masked time.”
Final component quality
Filters also influence hemolysis in red blood cells or platelet activation in PC. An invisible variable… but one that determines therapeutic value.
Conclusion – there is no such thing as a “perfect” filter. The right filter is the one that fits your process, your priorities, and your patients.
And you, which of these criteria weighs the most in your decisions?”
Stay updated on the emerging in transfusion medicine with Hemostasis Today.
-
Aug 6, 2026, 15:53Pall T. Onundarson: Frail Elderly Korean Atrial Fibrillation Patients Do Worse If Switched to DOACs in a Nationwide Observational Study
-
Aug 6, 2026, 15:46Zain Khalpey: Left Atrial Appendage Closure vs Oral Anticoagulation in Atrial Fibrillation
-
Aug 6, 2026, 15:25Mohd Ashhad: Cryoprecipitate – A Small Blood Component with a Big Clinical Role
-
Aug 6, 2026, 15:19Faris Otmani: New Systematic Review Evaluates TAVR and SAVR in Low-Risk Patients
-
Aug 6, 2026, 15:13How a PERT Team Navigates Severe Pregnancy PE – JTH
-
Aug 6, 2026, 15:05Melissa Hollo: Are All MS Symptoms Really Due to MS?
-
Aug 6, 2026, 15:03Zubair Naimullah: Early Recognition of Deep Vein Thrombosis Can Save Lives
-
Aug 6, 2026, 14:45Leonard Valentino: Why Hemophilic Arthropathy Is More Than an Inflammatory Joint Disease
-
Aug 6, 2026, 14:31Scarlet R. Spain: Early Recognition of Adolescent Cerebral Venous Thrombosis